We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Read MoreHide Full Article
Key Takeaways
HALO expects Q3 revenue growth from higher royalties on Darzalex and Vyvgart Hytrulo amid robust demand.
Higher royalties and incremental sales of Hylenex and Xyosted are expected to support revenue growth.
HALO projects 2026 revenues of $1.84-$1.91 billion, with royalty revenues reaching $1.13-$1.17 billion.
We expect Halozyme Therapeutics (HALO - Free Report) to beat expectations when it reports third-quarter 2026 results on Nov. 5, after market close. The Zacks Consensus Estimate for third-quarter sales and earnings is pegged at $480.7 million and $2.28 per share, respectively.
Let’s see how things might have shaped up before the announcement.
Year to date, shares of Halozyme have surged 94.9% compared with the industry’s rise of 8.4%.
Image Source: Zacks Investment Research
Factors Likely to Influence HALO's Q3 Results
Halozyme has collaboration agreements with large pharma companies that use its novel drug delivery technology, ENHANZE, for the development of subcutaneous (SC) formulations of their various marketed drugs. These agreements generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.
Halozyme has several marketed partnered drugs based on this technology, including the SC formulation of J&J’s (JNJ - Free Report) Darzalex, argenx’s Vyvgart Hytrulo and Roche’s Phesgo.
Halozyme’s top line in the third quarter is likely to have been driven by higher royalty payments from J&J for SC Darzalex as well as argenx’s Vyvgart Hytrulo due to robust demand. Our model estimates Halozyme's revenues from royalties to increase at a CAGR of 16.2% over the next three years.
Halozyme has two commercial proprietary products, Hylenex and Xyosted, with the latter acquired from Antares Pharma in 2022. Incremental sales from these products are also likely to have boosted Halozyme’s revenues during the upcoming quarter.
Revenues under collaborative agreements increased substantially in the last quarter, a trend that is most likely to have continued in the third quarter.
Reflecting the strong business performance, Halozyme raised its full-year 2026 financial outlook. The company now expects total revenues in the range of $1.84-$1.91 billion in 2026, representing year-over-year growth of 31% to 37%. Royalty revenues are expected to reach $1.13-$1.17 billion in 2026, representing year-over-year growth of 41% to 43%.
Investors will be keen to know whether the company increases the guidance further or maintains it on the upcoming earnings call.
HALO’s Earnings Surprise History
Halozyme has a mixed history of earnings surprises. The company beat on earnings in three of the trailing four quarters while missing the same on the remaining occasion, delivering an average negative surprise of 19.12%. In the last reported quarter, HALO posted an earnings surprise of 25.27%.
Halozyme Therapeutics, Inc. Price and EPS Surprise
Our proven model predicts an earnings beat for Halozyme this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here.
Earnings ESP: Halozyme’s Earnings ESP is +2.78%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are two drug/biotech stocks that also have the right combination of elements to beat on earnings this time around:
Amneal Pharmaceuticals (AMRX - Free Report) has an Earnings ESP of +4.17% and a Zacks Rank #2.
Amneal’s stock has surged 69.5% so far this year. AMRX beat estimates in each of the last four quarters. The company has a four-quarter earnings surprise of 32.82%, on average. Amneal is scheduled to report third-quarter results on Nov. 3.
Pfizer (PFE - Free Report) has an Earnings ESP of +3.53% and a Zacks Rank #3 at present.
Shares of Pfizer have risen 26.5% so far this year. Pfizer beat earnings estimates in each of the last four reported quarters, delivering an average earnings surprise of 16.62%. Pfizer is scheduled to report third-quarter results on Nov. 3.
View the Zacks #1 Rank List
Image: Bigstock
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Key Takeaways
We expect Halozyme Therapeutics (HALO - Free Report) to beat expectations when it reports third-quarter 2026 results on Nov. 5, after market close. The Zacks Consensus Estimate for third-quarter sales and earnings is pegged at $480.7 million and $2.28 per share, respectively.
Let’s see how things might have shaped up before the announcement.
Year to date, shares of Halozyme have surged 94.9% compared with the industry’s rise of 8.4%.
Image Source: Zacks Investment Research
Factors Likely to Influence HALO's Q3 Results
Halozyme has collaboration agreements with large pharma companies that use its novel drug delivery technology, ENHANZE, for the development of subcutaneous (SC) formulations of their various marketed drugs. These agreements generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.
Halozyme has several marketed partnered drugs based on this technology, including the SC formulation of J&J’s (JNJ - Free Report) Darzalex, argenx’s Vyvgart Hytrulo and Roche’s Phesgo.
Halozyme’s top line in the third quarter is likely to have been driven by higher royalty payments from J&J for SC Darzalex as well as argenx’s Vyvgart Hytrulo due to robust demand. Our model estimates Halozyme's revenues from royalties to increase at a CAGR of 16.2% over the next three years.
Halozyme has two commercial proprietary products, Hylenex and Xyosted, with the latter acquired from Antares Pharma in 2022. Incremental sales from these products are also likely to have boosted Halozyme’s revenues during the upcoming quarter.
Revenues under collaborative agreements increased substantially in the last quarter, a trend that is most likely to have continued in the third quarter.
Reflecting the strong business performance, Halozyme raised its full-year 2026 financial outlook. The company now expects total revenues in the range of $1.84-$1.91 billion in 2026, representing year-over-year growth of 31% to 37%. Royalty revenues are expected to reach $1.13-$1.17 billion in 2026, representing year-over-year growth of 41% to 43%.
Investors will be keen to know whether the company increases the guidance further or maintains it on the upcoming earnings call.
HALO’s Earnings Surprise History
Halozyme has a mixed history of earnings surprises. The company beat on earnings in three of the trailing four quarters while missing the same on the remaining occasion, delivering an average negative surprise of 19.12%. In the last reported quarter, HALO posted an earnings surprise of 25.27%.
Halozyme Therapeutics, Inc. Price and EPS Surprise
Halozyme Therapeutics, Inc. price-eps-surprise | Halozyme Therapeutics, Inc. Quote
What Our Model Says for HALO
Our proven model predicts an earnings beat for Halozyme this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here.
Earnings ESP: Halozyme’s Earnings ESP is +2.78%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Halozyme currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks to Consider
Here are two drug/biotech stocks that also have the right combination of elements to beat on earnings this time around:
Amneal Pharmaceuticals (AMRX - Free Report) has an Earnings ESP of +4.17% and a Zacks Rank #2.
Amneal’s stock has surged 69.5% so far this year. AMRX beat estimates in each of the last four quarters. The company has a four-quarter earnings surprise of 32.82%, on average. Amneal is scheduled to report third-quarter results on Nov. 3.
Pfizer (PFE - Free Report) has an Earnings ESP of +3.53% and a Zacks Rank #3 at present.
Shares of Pfizer have risen 26.5% so far this year. Pfizer beat earnings estimates in each of the last four reported quarters, delivering an average earnings surprise of 16.62%. Pfizer is scheduled to report third-quarter results on Nov. 3.